Runway Growth Finance (RWAY) is currently trading at a significant 45% discount to its net asset value (NAV) while offering a fully covered dividend yield of 20%. The company's recent acquisition of SWK has improved net investment income growth, dividend coverage, and the risk profile of its portfolio, reversing previous negative trends. Despite these positives, concerns remain due to rising non-accrual loans and potential declines in the portfolio's value. Management remains confident in maintaining full-year dividend coverage, but the elevated risks lead to a cautious Hold rating for investors.
Runway Growth Finance's current market context is provided for readers following financial stocks. Among 74 priced Financials-sector US stocks tradable on Pluang, only 13 rose while 60 fell today. Notably, BNY (Bank of New York Mellon Corp) declined by 2.47% to USD 153.77, KB (KB Financial Group, Inc.) dropped 2.45% to USD 129.63, and MS (Morgan Stanley) decreased 2.30% to USD 201.85, as of Sep 15, 2026 21:41 WIB.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
